Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

European Respiratory Journal

Volumn 28, Issue 4, 2006, Pages 691-694

  Hoeper, Marius M ^a   Leuchte, H ^b   Halank, M ^c   Wilkens, H ^d   Meyer, F J ^e   Seyfarth, H J ^f   Wensel, R ^g   Ripken, F ^a   Bremer, H ^h   Kluge, S ⁱ   Hoeffken, G ^c   Behr, J ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g UNIVERSITY OF REGENSBURG   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Endothelin receptor antagonists; Prostaglandins; Pulmonary hypertension

Indexed keywords

BOSENTAN; ILOPROST; ANTIHYPERTENSIVE AGENT; SULFONAMIDE; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLUSHING; FUNCTIONAL STATUS; HEMOPTYSIS; HUMAN; LUNG CAPACITY; MALE; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; OXYGEN CONSUMPTION; PHASE 4 CLINICAL TRIAL; PHYSICAL CAPACITY; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; DRUG COMBINATION; EXERCISE TEST; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED;

ADMINISTRATION, INHALATION; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; EXERCISE TEST; FEMALE; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MALE; MIDDLE AGED; SULFONAMIDES; VASODILATOR AGENTS;

EID: 33847368988     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00057906     Document Type: Article

References (14)

1. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
2. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
3. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.
4. Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 2005; 26: 1895-1902.
5. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27: 589-595.
6. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003, 42: 158-164.
7. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003; 22: 330-334.
8. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24: 1007-1010.
9. Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol 2005; 96: 1334-1336.
10. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26: 858-863.
11. Hoeper MM, Dinh-Xuan AT. Combination therapy for pulmonary arterial hypertension: still more questions than answers. Eur Respir J 2004; 24: 339-340.
12. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 5S-12S.
13. EuroQol Group, EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
14. Seyfarth HJ, Pankau H, Hammerschmidt S, Schauer J, Wirtz H, Winkler J. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest 2005; 128: 709-713.